ImmuCell boosts Q2 sales guidance as inventory management improves

Maine-based ImmuCell ($ICCC) said on Wednesday that it is increasing its sales forecast for the second quarter as it works to fulfill "pent-up demand" that's building for First Defense, its medicine that protects calves from the disease scours. During the company's first-quarter earnings announcement, executives admitted that they couldn't keep up with the $1.3 million backlog of orders that was continuing to build. That backlog has now grown to $1.45 million, the company said in a press release, but a "better-than-expected inventory production schedule" has led to a sunnier sales forecast. ImmuCell now expects its product sales to grow 25% to 30% year-over-year in the second quarter, vs. the 15% to 20% growth it was predicting before. The company recorded product sales of $1.5 million in the second quarter of 2014. Release (PDF)

Suggested Articles

Payers are now holding up Spark's $850,000 gene therapy as an example of how innovative drug developers can help payers afford pricey new treatments.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…

After two years of implementing an across-the-board efficiency plan, fine-tuning its product portfolio and getting manufacturing up to speed on Apoquel, animal…